Aquestive Therapeutics, Inc. Common Stock (AQST) Stock
Key stats
- Market cap
- $449.96M
- Price / Earnings ratio
- -5.6x
- EPS (TTM)
- -$0.65
- Volume
- Loading
- 52-week high
- $6.74
- 52-week low
- $2.93
Source: third-party data provider, as of November 13, 2026
Compare with AQST
Recent news

Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
AQST

Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics Q2 Earnings Call Highlights
AQST

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
AQST

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
AQST
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.10
- MACD 12/26/9
- -0.24
- EMA 9 of MACD
- -0.22
- MACD histogram
- -0.02
- SMA 50
- $4.44
- Price below SMA 50
- EMA 50
- $4.20
- Price below EMA 50
- SMA 200
- $4.22
- Price below SMA 200
- EMA 200
- $4.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
AQST

Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics Q2 Earnings Call Highlights
AQST

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
AQST

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
AQST

Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics Q1 Earnings Call Highlights
AQST

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
AQST

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
AQST

AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
AQST

Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
AQST

Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
AQST
News tone: automated (AI) classification of the article's content, not a price prediction.
About Aquestive Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Barber | CEO, President & Director | 1976 |
| Mr. A. Ernest Toth Jr. | Senior VP & CFO | 1959 |
| Ms. Cassie Jung | Chief Operating Officer | 1979 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Corporate Secretary | 1956 |
| Mr. Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer | 1972 |
| Mr. Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer | 1966 |
| Dr. Matthew Greenhawt B.Sc., M.B.A., M.D. | Chief Medical Officer | 1974 |
| Ms. Sherry Korczynski | Chief Commercial Officer | 1970 |
| Dr. Melina T. Cioffi Pharm.D. | Senior Vice President of Regulatory Affairs | 1983 |
| Dr. Matthew William Davis M.D., R.Ph. | Chief Development Officer | 1966 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.10
- MACD 12/26/9
- -0.24
- EMA 9 of MACD
- -0.22
- MACD histogram
- -0.02
- SMA 50
- $4.44
- Price below SMA 50
- EMA 50
- $4.20
- Price below EMA 50
- SMA 200
- $4.22
- Price below SMA 200
- EMA 200
- $4.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $10.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.3 | -31.6 | ||||||||||
| 2022 | -36.2 | -1.8 | -9.4 | -45.5 | -29.8 | -34.7 | +30.2 | +68.6 | -9.3 | -26.3 | +8.1 | -3.2 |
| 2023 | -1.1 | -11.4 | +48.1 | +26.4 | +66.2 | -28.6 | +36.0 | -26.8 | -8.4 | +12.1 | +46.1 | -15.5 |
| 2024 | +18.9 | +37.5 | +0.5 | -18.6 | -14.5 | -11.6 | +56.7 | +26.2 | +18.9 | +15.3 | -7.8 | -26.0 |
| 2025 | -17.7 | -3.1 | +9.4 | +2.4 | -9.7 | +17.8 | +12.9 | -1.3 | +46.0 | +16.0 | -4.6 | +4.2 |
| 2026 | -54.3 | -2.4 | -1.4 | -0.7 | -4.3 | +4.0 | -12.7 | +34.8 | -11.6 | -12.4 | -5.0 |



